Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD

Journal of Clinical Pharmacology

Volumn 48, Issue 11, 2008, Pages 1300-1308

  Tronde, Ann ^a   Gillen, Michael ^b   Borgström, Lars ^a   Lötvall, Jan ^c   Ankerst, Jaro ^d  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Budesonide; Budesonide formoterol pMDI; Combination inhaler; Formoterol; Pharmacokinetics

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MONOTHERAPY; POWDER INHALER;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; BIOLOGICAL AVAILABILITY; BUDESONIDE; CHILD; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; YOUNG ADULT;

EID: 54049119717     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008322122     Document Type: Article

References (36)

1. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute ; 2007. NHLBI publication no. 08-4051.
2. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2005 Update. Available at: http://www.goldcopd.com/download.asp?intId= 234.
3. Calverley PM, Boonsawat W., Cseke Z., Zhong N., Peterson S., Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003 ; 22: 912-919.
4. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic pulmonary disease: a randomised controlled trial. Lancet. 2003 ; 361: 449-456.
5. Hanania NA, Darken P., Horstman D., et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 ; 124: 834-843.
6. Mahler DA, Wire P., Horstman D., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 ; 166: 1084-1091.
7. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003 ; 21: 74-81.
8. Banov CH The role of budesonide in adults and children with mild-to-moderate persistent asthma. J Asthma. 2004 ; 41: 5-17.
9. Berger WE The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006 ; 97: 24-33.
10. Lalloo UG, Malolepszy J., Kozma D., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to moderate asthma. Chest. 2003 ; 123: 1480-1487.
11. Tal A., Simon G., Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002 ; 34: 342-350.
12. Zetterström O., Buhl R., Mellem H., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001 ; 18: 262-268.
13. Rosenhall L., Elvstrand A., Tilling B., et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort® Turbuhaler®) for the treatment of asthma. Respir Med. 2003 ; 97: 702-708.
14. Agertoft L., Laulund LW, Harrison LI, Pedersen S. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol. 2003 ; 35: 192-199.
15. Donnelly R., Seale JP Clinical pharmacokinetics of inhaled budesonide. Clin Pharmacokinet. 2001 ; 40: 427-440.
16. Agertoft L., Andersen A., Weibull E., Pedersen S. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child. 1999 ; 80: 241-247.
17. Brutsche MH, Brutsche IC, Munawar M., et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000 ; 356: 556-561.
18. McCormack PL, Lyseng-Williamson KA Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma. Drugs. 2007 ; 67: 2407-2431.
19. Derom E., Strandgården K., Schelfhout V., Borgström L., Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007 ; 101: 1931-1941.
20. Noonan M., Rosenwasser L., Martin P., O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006 ; 66: 2235-2254.
21. Corren J., Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007 ; 29: 823-843.
22. Miller CJ, Senn S., Mezzanotte WS Bronchodilation of formoterol administered with budesonide: device and formulation effects. Contemp Clin Trials. 2008 ; 29: 114-124.
23. Zitt MJ Properties of the ideal corticosteroid therapy. Allergy Asthma Proc. 2005 ; 26: 173-182.
24. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002 ; 165: 1377-1383.
25. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1992 ; 44: 375-407.
26. Agertoft L., Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000 ; 343: 1064-1069.
27. Källén B., Rydhstroem H., Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999 ; 93: 392-395.
28. Ericson A., Källén B. Use of drugs during pregnancy: unique Swedish registration method that can be improved. Swedish Medical Products Agency. 1999 ; 1: 8-11.
29. Norjavaara E., Gerhardsson de Verdier M. Normal pregnancy outcomes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003 ; 111: 736-742.
30. Fält A., Bengtsson T., Kennedy BM, et al. Exposure of infants to budesonide through breast milk of asthmatic mothers. J Allergy Clin Immunol. 2007 ; 120: 798-802.
31. Borgström L., Olsson B., Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006 ; 19: 473-483.
32. Berg E. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med. 1995 ; 8: S3 - S11.
33. Anhøj J., Thorsson L., Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med. 2000 ; 162: 1819-1822.
34. Thorsson L., Kenyon C., Newman SP, Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm. 1998 ; 168: 119-127.
35. Sovani MP, Whale CI, Tattersfield AE A benefit-risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease. Drug Saf. 2004 ; 27: 689-715.
36. Lecaillon JB, Kaiser G., Palmisano M., Morgan J., Della Cioppa G. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer™. Eur J Clin Pharmacol. 1999 ; 55: 131-138.